Skip to main content
. 2012 Jul 20;1:18. doi: 10.1186/2162-3619-1-18

Table 3.

Studies on clinical significance of E2F1 expression in NSCLC

Study/year1 Patient number Adenocarcinoma/SCC Assay used Incidence of E2F1 overexpression Survival difference
Volm/1998
96
0/96
IHC
24%
No
Gorgoulis/2002
77
37/37
IHC
49%
Yes
Huang/2007
127
63/58
Quantitative RT-PCR
40%
Yes
Hung/2012 56 33/20 Western blot 38% No

1Last name of the first author/year of publication.

SCC squamous cell carcinoma, IHC immunohistochemistry.